论文部分内容阅读
目的探讨低剂量吉西他滨单药治疗老年晚期非小细胞肺癌的临床疗效。方法将我院60例非小细胞肺癌老年患者,随机分为两组各30例,观察组静脉滴注吉西他滨,600ml/m-2,30min/次,周期1个月;对照组给予最佳支持治疗,评价两组临床疗效。结果观察组临床获益率、总有效率、1年生存率均显著高于对照组(P<0.05)。结论低剂量吉西他滨治疗老年晚期非小细胞肺癌疗效确切,毒副反应可耐受,值得临床推广。
Objective To investigate the clinical efficacy of low-dose gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. Methods 60 elderly patients with non-small cell lung cancer in our hospital were randomly divided into two groups of 30 patients. The observation group received gemcitabine infusion of 600ml / m-2, 30min / time and 1-month cycle. The control group received the best support Treatment, evaluation of two groups of clinical curative effect. Results The clinical benefit rate, total effective rate and 1-year survival rate in the observation group were significantly higher than those in the control group (P <0.05). Conclusion Low-dose gemcitabine for the treatment of elderly patients with advanced non-small cell lung cancer is effective, tolerable side effects, worthy of clinical promotion.